Oral antivirals for mild-moderate COVID-19: a panacea or a logistical and clinical conundrum?

Ian D Coombes; Amy Legg; Tina Patterson; Tanya Kelly; Andrew Henderson; Jason A Roberts

doi:10.18773/austprescr.2022.021

Oral antivirals for mild-moderate COVID-19: a panacea or a logistical and clinical conundrum?

Aust Prescr. 2022 Apr;45(2):67-68. doi: 10.18773/austprescr.2022.021. Epub 2022 Mar 24.

Authors

Ian D Coombes^{1

2

3

4

5

6

7

8

9

10

11

12

13}, Amy Legg^{1

2

3

4

5

6

7

8

9

10

11

12

13}, Tina Patterson^{1

2

3

4

5

6

7

8

9

10

11

12

13}, Tanya Kelly^{1

2

3

4

5

6

7

8

9

10

11

12

13}, Andrew Henderson^{1

2

3

4

5

6

7

8

9

10

11

12

13}, Jason A Roberts^{1

2

3

4

5

6

7

8

9

10

11

12

13}

Affiliations

¹ Department of Pharmacy, Royal Brisbane and Women's Hospital.
² Department of Pharmacy, University of Queensland, Brisbane.
³ COVID-19 Medicines, Pharmacy Planning and Response Group.
⁴ Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane.
⁵ COVID-19 Clinical Therapeutic Guideline Working Group.
⁶ Department of Pharmacy, Logan Hospital, Brisbane.
⁷ Department of Anaesthesia and Perioperative Medicine, Sunshine Coast University Hospital, Queensland.
⁸ Queensland Clinical Senate, Clinical Excellence Queensland.
⁹ Department of Infectious Diseases, Princess Alexandra Hospital, Brisbane.
¹⁰ University of Queensland Centre for Clinical Research, Faculty of Medicine, Brisbane.
¹¹ Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital.
¹² Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes France.
¹³ Full author details available online.

No abstract available

Keywords: COVID-19; SARS-CoV-2; molnupiravir; nirmatrelvir/ritonavir; quality use of medicines.

Publication types

Editorial